PSNL News and Press, Personalis Inc. From 09/26/19

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced a new task order under its contract with the U.S. Department of Veterans Affairs (VA) for the VA’s Million Veteran Program (VA MVP). The new task order is effective on September 28, 2019. This is...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that it has appointed Karin Eastham as an independent director to its Board of Directors. Ms. Eastham brings more than 36 years of experience as both an executive and as an independent director in the b...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that it has entered into a research agreement with Invectys, a biopharmaceutical company focused on the development of innovative immunotherapy approaches to treat cancers. Under the terms of the agreem...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the company will participate at the upcoming 17th Annual Morgan Stanley Global Healthcare Conference being held from September 9-11, 2019 in New York, NY. Personalis is scheduled to participate in a...

Personalis ( PSNL ) has been a stock which has gathered my interest since the company went public in the second half of June this year. I reviewed the prospects for the company in this article, titled " Personalis: Potential Personal Genomics Growth Champion ". The business potential is cert...

Personalis, Inc. (PSNL) Q2 2019 Earnings Conference Call August 13, 2019, 17:00 ET Company Participants Caroline Corner - IR John West - President & CEO Aaron Tachibana - CFO Clinton Musil - Chief Business Officer Richard Chen - Chief Scientific Officer Conference Call...

Personalis (NASDAQ: PSNL ): Q2 GAAP EPS of -$0.89 misses by $0.61 . More news on: Personalis, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today reported financial results for the second quarter ended June 30, 2019. Second Quarter 2019 Highlights Record revenues of $15.8 million in the second quarter of 2019, versus $8.8 million in the second ...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that The University of New Mexico (UNM) Comprehensive Cancer Center and the New Mexico Alliance for Cancer Care will utilize Personalis’ cancer immunogenomics platform, ImmunoID NeXT ™, f...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the latest expansion of its universal cancer immunogenomics platform, ImmunoID NeXT , incorporating several additional features that are pivotal to the understanding of tumor and immune cell interactio...